News Perspective Therapeutics, Inc.

Stocks

CATX

US46489V3024

Biotechnology & Medical Research

Market Closed - NYSE 04:00:00 2026-09-18 pm EDT			5-day change	1st Jan Change
2.880 ^USD	0.00%		+2.49%	+4.73%

Sep. 18	William Blair Initiates Perspective Therapeutics With Outperform Rating	MT
Sep. 14	Perspective Therapeutics, Inc. and Merck Announce Clinical Collaboration and Supply Agreement to Evaluate [212Pb]PSV359 in Combination with Keytruda (Pembrolizumab) in FAP-a Positive Solid Tumors	CI

All News

Mentions Relevance

Sep. 18	William Blair Initiates Perspective Therapeutics With Outperform Rating	MT
Sep. 14	Perspective Therapeutics, Inc. and Merck Announce Clinical Collaboration and Supply Agreement to Evaluate [212Pb]PSV359 in Combination with Keytruda (Pembrolizumab) in FAP-a Positive Solid Tumors	CI
Sep. 14	Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell	MT
Sep. 14	Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors	AQ
Sep. 11	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026	AQ
Aug. 19	BMO Capital Initiates Perspective Therapeutics at Outperform	MT
Aug. 14	BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6	MT
Aug. 11	Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says	MT
Aug. 10	Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results	AQ
Aug. 10	Perspective Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jul. 31	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results	AQ
Jul. 28	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation	MT
Jul. 28	Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs	AQ
Jul. 17	Perspective Therapeutics Data On 212Pb VMT-a-NET Accepted For Oral Presentation At ESMO Congress 2026	CI
Jul. 17	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026	AQ
Jul. 08	Perspective Therapeutics, Inc. Announces Executive Changes	CI
Jul. 08	Perspective Therapeutics Names Paul Lyne Chief Science Officer as Co-Founder Michael Schultz Moves to Advisory Role	MT
Jul. 08	Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor	AQ
Jun. 03	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort	MT
Jun. 03	Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study	AQ
Jun. 03	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI
May. 21	Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma	AQ
May. 18	Perspective Therapeutics, Inc. Announces First Patients Dosed In New Cohorts Of Ongoing Phase 1/2a Studies	CI
May. 18	Perspective Therapeutics Doses First Patients for New Cohorts of Two Phase 1/2a Studies in Tumors	MT
May. 18	Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies	AQ